Difference between revisions of "Abexinostat (PCI-24781)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
===[[Follicular lymphoma]]; [[Mantle cell lymphoma]]=== | ===[[Follicular lymphoma]]; [[Mantle cell lymphoma]]=== | ||
| − | # Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clin Cancer Res. 2016 Mar 1;22(5):1059-66. Epub 2015 Oct 19. [http://clincancerres.aacrjournals.org/content/22/5/1059.full link to original article] [https://www.ncbi.nlm.nih.gov/ | + | # Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clin Cancer Res. 2016 Mar 1;22(5):1059-66. Epub 2015 Oct 19. [http://clincancerres.aacrjournals.org/content/22/5/1059.full link to original article] [https://pubmed.ncbi.nlm.nih.gov/26482040/ PubMed] |
| + | # Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study. Haematologica. 2017 May;102(5):903-909. Epub 2017 Jan 25. [http://www.haematologica.org/content/102/5/903 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28126962/ PubMed] | ||
| − | [[Category: | + | ==Also known as== |
| − | [[Category: | + | *'''Code name:''' PCI-24781 |
| + | |||
| + | [[Category:Drugs]] | ||
| + | |||
| + | [[Category:Oral medications]] | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| − | [[Category:Follicular lymphoma medications]] | + | [[Category:Follicular lymphoma medications (investigational)]] |
| − | [[Category:Mantle cell lymphoma medications]] | + | [[Category:Mantle cell lymphoma medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 14:21, 26 April 2023
Mechanism of action
From the NCI Drug Dictionary: A novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Abexinostat inhibits several isoforms of HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis.
Preliminary data
Follicular lymphoma; Mantle cell lymphoma
- Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clin Cancer Res. 2016 Mar 1;22(5):1059-66. Epub 2015 Oct 19. link to original article PubMed
- Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study. Haematologica. 2017 May;102(5):903-909. Epub 2017 Jan 25. link to original article PubMed
Also known as
- Code name: PCI-24781